• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates

Acorda Therapeutics

Acorda Therapeutics announces departure of business operations chief

February 19, 2021 By Sean Whooley Leave a Comment

Acorda Therapeutics (NSDQ:ACOR) announced today that its chief of business operations, David Lawrence, is resigning from the company. Lawrence, who also serves as Acorda’s principal accounting and financial officer, is resigning effective mid-March 2021 as he is set to take a leadership position at an early-stage biotechnology company, according to a news release. Get the full […]

Filed Under: Business/Financial News, Drug-Device Combinations, Pharmaceutical Tagged With: Acorda Therapeutics, Personnel Moves

Acorda’s Parkinson’s device moves closer to E.U. approval

July 26, 2019 By Nancy Crotti

Acorda Therapeutics (NSDQ:ACOR) said today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of its Inbrija device for the intermittent treatment of  “off” episodes in people with Parkinson’s disease. The self-administered, inhaled therapy is designed for people experiencing a re-emergence of Parkinson’s symptoms. These “off” episodes are caused by low […]

Filed Under: Blog, Business/Financial News, Drug-Device Combinations, Featured, Regulatory/Compliance Tagged With: Acorda Therapeutics, European Medicines Agency (EMA), European Union

Acorda wins FDA nod for inhaled Parkinson’s therapy

December 26, 2018 By Sarah Faulkner

Acorda Therapeutics (NSDQ:ACOR) said this week that the FDA approved its Inbrija device for the intermittent treatment of  “off” episodes in people with Parkinson’s disease. The self-administered, inhaled therapy is designed for people experiencing a re-emergence of Parkinson’s symptoms. These “off” episodes are caused by low levels of dopamine between doses of the standard oral Parkinson’s […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Neurological, Pharmaceutical, Regulatory/Compliance, Wall Street Beat Tagged With: Acorda Therapeutics

FDA pushes back decision date for Acorda’s Parkinson’s drug

September 13, 2018 By Sarah Faulkner

Acorda Therapeutics (NSDQ:ACOR) said today that the FDA pushed back its goal date for the agency’s review of Acorda’s inhaled levodopa Parkinson’s therapy. The FDA’s date to make a decision about Acorda’s Inbrija product was moved from Oct. 5, 2018 to Jan. 5, 2019. The Ardsley, N.Y.-based company said the extension is related to submissions it […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Neurological, Pharmaceutical, Regulatory/Compliance, Wall Street Beat Tagged With: Acorda Therapeutics

Acorda’s CEO on failure, perseverance and the profound risks of drug development

July 25, 2018 By Sarah Faulkner

Dr. Ron Cohen isn’t easily deterred. The physician-turned-executive has spent decades in the biotech industry and weathered a number of setbacks – he learned in his early years at the now-defunct Advanced Tissue Sciences that to succeed, he needed resilience. “I learned that it took hundreds of millions of dollars if not billions to develop […]

Filed Under: Biotech, Drug-Device Combinations, Food & Drug Administration (FDA), Neurological, Pharmaceutical, Regulatory/Compliance, Wall Street Beat Tagged With: Acorda Therapeutics, Massachusetts Institute of Technology

Sunovion seeks FDA nod for sublingual film to treat Parkinson’s disease

March 30, 2018 By Sarah Faulkner

Sunovion Pharmaceuticals submitted a new drug application to the FDA this week for its apomorphine sublingual film designed to treat motor fluctuations experienced by people with Parkinson’s disease. The Marlborough, Mass.-based company is testing the film as a therapy for Parkinson’s patients experiencing “off” episodes – when symptoms that are otherwise controlled by medications resurface. As […]

Filed Under: Clinical Trials, Drug-Device Combinations, Food & Drug Administration (FDA), Neurological, Pharmaceutical, Regulatory/Compliance, Wall Street Beat Tagged With: Acorda Therapeutics, Sunovion Pharmaceuticals

Acorda seeks EU approval for inhaled Parkinson’s disease drug

March 26, 2018 By Sarah Faulkner

Acorda Therapeutics (NSDQ:ACOR) submitted a marketing authorization application to the European Medicines Agency for its inhaled Parkinson’s disease therapy, Inbrija, according to the Ardsley, N.Y.-based company. The investigational drug is designed to treat people with Parkinson’s disease who are experiencing “off” periods, or a re-emergence of symptoms. Get the full story at our sister site, Drug […]

Filed Under: Drug-Device Combinations, Food & Drug Administration (FDA), Neurological, Pharmaceutical, Regulatory/Compliance, Wall Street Beat Tagged With: Acorda Therapeutics

Acorda Therapeutics wins FDA NDA nod for Inbrija

February 20, 2018 By Fink Densford

Acorda Therapeutics (NSDQ:ACOR) said today that the FDA accepted the New Drug Application for its Inbrija investigational inhaled levodopa product designed for treating symptoms of OFF periods in patients with Parkinson’s disease who are taking carbidopa/levodopa regimens. The approval comes with a target date of October 5, 2018, the Ardsley, N.Y.-based company said. Read the whole story […]

Filed Under: Food & Drug Administration (FDA), Neurological, Regulatory/Compliance, Respiratory Tagged With: Acorda Therapeutics

Acorda posts Q4 revenue beat, but misses EPS estimates

February 15, 2018 By Sarah Faulkner

Shares in Acorda Therapeutics (NSDQ:ACOR) fell today after the biotech company met sales expectations on Wall Street with its fourth-quarter results, but missed EPS estimates. The Ardsley, N.Y.-based company posted a net loss of -$171 million on sales of $188.4 million for the 3 months ended Dec.31, for sales growth of 34% compared with the same period last […]

Filed Under: Drug-Device Combinations, MassDevice Earnings Roundup, Pharmaceutical, Wall Street Beat Tagged With: Acorda Therapeutics

Sunovion touts pivotal Ph3 trial for Parkinson’s drug

January 30, 2018 By Sarah Faulkner

Gearing up for a springtime FDA submission, Sunovion Pharmaceuticals reported today that its apomorphine sublingual film succeeded in a pivotal Phase III trial in patients with Parkinson’s disease who experience motor fluctuations. Without revealing the study’s full results, the Marlborough, Mass.-based company said that the trial met its primary and key secondary endpoints and that the drug […]

Filed Under: Clinical Trials, Drug-Device Combinations, Neurological, Pharmaceutical, Wall Street Beat Tagged With: Acorda Therapeutics, Sunovion Pharmaceuticals

Acorda resubmits NDA for inhaled Parkinson’s disease therapy

December 7, 2017 By Sarah Faulkner

Acorda Therapeutics (NSDQ:ACOR) said today that it resubmitted its new drug application for Inbrija, an inhaled therapy for people with Parkinson’s disease. The Ardsley, N.Y.-based company was dealt a setback in August when the FDA told Acorda that it wouldn’t review its application for Inbrija, a move that sent ACOR shares tumbling. Get the full story at […]

Filed Under: Drug-Device Combinations, Food & Drug Administration (FDA), Pharmaceutical, Regulatory/Compliance, Respiratory, Wall Street Beat Tagged With: Acorda Therapeutics

  • Go to page 1
  • Go to page 2
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS